 "Aurobindo Pharma hits record high on USFDA tentative nod for Lacosamide tablets")
Shares of Aurobindo Pharma were trading higher by 2% at Rs 1,265 on the BSE after the drug maker announced that US Food and Drug Administration (USFDA) has granted the tentative approval for Lacosamide tablets 50mg, 100mg, 150mg and 200mg.
Lacosamide tablets are the generic equivalent of USB Inc’s Vimpat tablets and used in the treatment of partial-onset seizures in patients with epilepsy aged 17 years and older.
According to IMS, a market size of Lacosamide tablets is approximately US$ 593 million for the twelve months ended January 2015, Aurobindo Pharma said in a release.
The stock opened at Rs 1,252 and hit a record high of Rs 1,279 on the BSE. A combined 1.52 million shares changed hands on the counter till 1448 hours on the BSE and NSE.
Lacosamide tablets are the generic equivalent of USB Inc’s Vimpat tablets and used in the treatment of partial-onset seizures in patients with epilepsy aged 17 years and older.
According to IMS, a market size of Lacosamide tablets is approximately US$ 593 million for the twelve months ended January 2015, Aurobindo Pharma said in a release.
The stock opened at Rs 1,252 and hit a record high of Rs 1,279 on the BSE. A combined 1.52 million shares changed hands on the counter till 1448 hours on the BSE and NSE.